Research has shown that nearly 50% of patients suffering from soft tissue sarcoma develop lung tumors. Presently, pulmonary metastasectomy, which is the surgical removal of lung tumors, is the primary treatment option for the disease as effective systemic treatments for metastatic soft tissue sarcoma are scarce. Despite this, guidelines for performing a pulmonary metastasectomy for soft tissue sarcoma don’t exist. and decisions to carry out the surgery are usually made on a person-to-person basis.
During the 96th annual American Association for Thoracic Surgery meeting, scientists from the Memorial Sloan Kettering Cancer Center gave a presentation on prognostic factors and survival data of more than 500 patients with pulmonary metastases from soft tissue sarcoma who had undergone pulmonary mestastasectomies. The presentation was based off of a huge database of soft tissue sarcoma patients, all from one institution.
More than 10,000 new cases of soft tissue sarcoma are diagnosed in the United States every year, with nearly half of this number succumbing to the illness. Almost half of soft tissue sarcoma patients also develop one or more lung tumors, and without efficacious systemic therapies, clinicians usually rely on the surgical removal of these tumors as the primary mode of treatment.
Dr. Neel Chudgar from the Memorial Sloan Center’s Department of Surgery stated that the study was different from prior publications because they utilized a bigger cohort from one institution, which increased the power to potentially determine notable differences. Chudgar also explained that for their study, the researchers centered on soft tissue sarcoma solely to improve the homogeneity of the study population.
The database used in the study was made up of more than 800 patients who had undergone pulmonary metastasectomy for the soft tissue cancer between 1991 and 2014. The researchers did not include patients who didn’t undergo resections of their primary tumors, those who underwent pulmonary metastasectomies in other hospitals and those who suffered from primary bone sarcomas.
This led the researchers to the discovery that the intermediate illness-free survival rate was about six months while the overall survival after the primary pulmonary metastasectomy was roughly 33 months. In addition, almost 35% of patients were alive after five years while about 20% were alive after seven years.
The scientists then analyzed the data in an attempt to determine the factors linked to prolonged survival and discovered that no more than a trio of primary lung tumors, increasing time from initial tumor resection to development of pulmonary tumors, initial tumor size of no more than 10 cm and leiomyosarcoma histologic subtype, were all significantly linked to longer overall survival.
Also, in comparison with open surgery, minimally invasive surgeries were also linked to longer overall survival.
Additionally, companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) are hard at work developing better remedies for soft tissue sarcomas, and their efforts could yield the superior solutions that patients and clinicians have been longing for.
NOTE TO INVESTORS: The latest news and updates relating to Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) available in the company’s newsroom at https://ibn.fm/TRYPF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Significant strides have been made in leveraging checkpoint inhibitor therapy to combat a number of cancers over the recent…
LIXTE recently expanded its ovarian clear cell cancer trial in partnership with MD Anderson and…
California, led by Democratic governor Gavin Newsom, has decided to break with the federal positions on public health and…
Earth Science Tech is a holding company that acquires and manages businesses in several markets,…
Prof. Brown is a leading researcher in Transcranial Magnetic Stimulation (“TMS”) and currently serves as…
South Korean scientists have published the results of a study that provides vital insights indicating…